Survival Benefit of Tamoxifen in Estrogen Receptor-negative and Progesterone Receptor-positive Low Grade Breast Cancer Patients

Overview

Journal J Breast Cancer

Date 2012 Oct 24

PMID 23091541

Citations 22

Authors

Li-Heng Yang

Hsin-Shun Tseng

Che Lin

Li-Sheng Chen

Shou-Tung Chen

Shou-Jen Kuo

Dar-Ren Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses.

Methods: Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up.

Results: The 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PR- tumors experienced the worst outcome (74% survival rate); whereas single-positive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p=0.01 and p=0.03, respectively).

Conclusion: For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.

Citing Articles

Cancer drug sensitivity prediction from routine histology images.

Dawood M, Vu Q, Young L, Branson K, Jones L, Rajpoot N NPJ Precis Oncol. 2024; 8(1):5.

PMID: 38184744 PMC: 10771481. DOI: 10.1038/s41698-023-00491-9.

circRNAs in drug resistance of breast cancer.

Misir S, Yaman S, Petrovic N, Sumer C, Hepokur C, Aliyazicioglu Y Oncol Res. 2023; 30(4):157-172.

PMID: 37304411 PMC: 10208077. DOI: 10.32604/or.2022.027547.

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer.

Fan Y, Zhong X, Wang Y, Wang Z, Luo T, Wang Y Breast Cancer Res Treat. 2023; 200(2):171-182.

PMID: 37199804 PMC: 10241679. DOI: 10.1007/s10549-023-06964-6.

ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.

Song C, Kendi A, Shim J, Jung D, Kang P, Lowe V Breast Cancer. 2023; 30(3):436-452.

PMID: 36859733 DOI: 10.1007/s12282-023-01437-6.

Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study.

Liu J, Gan M, Lin Z, Deng Q, Deng J, Zeng B Breast J. 2022; 2022:5469163.

PMID: 36531979 PMC: 9726250. DOI: 10.1155/2022/5469163.

References

Osborne C, Yochmowitz M, Knight 3rd W, McGuire W . The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980; 46(12 Suppl):2884-8. DOI: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. View

Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C . Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366(9484):455-62. DOI: 10.1016/S0140-6736(05)67059-6. View

Rakha E, El-Sayed M, Green A, Paish E, Powe D, Gee J . Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007; 25(30):4772-8. DOI: 10.1200/JCO.2007.12.2747. View

Anderson W, Chen B, Jatoi I, Rosenberg P . Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat. 2006; 100(1):121-6. DOI: 10.1007/s10549-006-9231-y. View

Cormack O, Harrison M, Kerin M, McCann A . Role of the progesterone receptor (PR) and the PR isoforms in breast cancer. Crit Rev Oncog. 2008; 13(4):283-301. DOI: 10.1615/critrevoncog.v13.i4.20. View

Olivotto I, Truong P, Speers C, Bernstein V, Allan S, Kelly S . Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol. 2004; 22(9):1769-70. DOI: 10.1200/JCO.2004.99.251. View

. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351(9114):1451-67. View

Piccart M, Di Leo A, Hamilton A . HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?. Eur J Cancer. 2000; 36(14):1755-61. DOI: 10.1016/s0959-8049(00)00162-3. View

Carey L, Perou C, Livasy C, Dressler L, Cowan D, Conway K . Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-502. DOI: 10.1001/jama.295.21.2492. View

10.

Osborne C, Schiff R, Arpino G, Lee A, Hilsenbeck V . Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005; 14(6):458-65. DOI: 10.1016/j.breast.2005.08.024. View

11.

Bird P, HILL A, Houssami N . Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?. Ann Surg Oncol. 2008; 15(7):1983-8. DOI: 10.1245/s10434-008-9900-7. View

12.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F . A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005; 11(13):4741-8. DOI: 10.1158/1078-0432.CCR-04-2569. View

13.

Berry D, Muss H, Thor A, Dressler L, Liu E, Broadwater G . HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000; 18(20):3471-9. DOI: 10.1200/JCO.2000.18.20.3471. View

14.

Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I . Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007; 25(19):2664-70. DOI: 10.1200/JCO.2006.08.8054. View

15.

Loprinzi C, Ravdin P, De Laurentiis M, Novotny P . Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer?. J Clin Oncol. 1994; 12(7):1422-6. DOI: 10.1200/JCO.1994.12.7.1422. View

16.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

17.

Coombes R, Hall E, Gibson L, Paridaens R, Jassem J, Delozier T . A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350(11):1081-92. DOI: 10.1056/NEJMoa040331. View

18.

Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham D, Fisher E . Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001; 19(4):931-42. DOI: 10.1200/JCO.2001.19.4.931. View

19.

Nikolic-Vukosavljevic D, Kanjer K, Neskovic-Konstantinovic Z, Vukotic D . Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. Int J Biol Markers. 2002; 17(3):196-200. DOI: 10.1177/172460080201700309. View

20.

Bardou V, Arpino G, Elledge R, Osborne C, Clark G . Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003; 21(10):1973-9. DOI: 10.1200/JCO.2003.09.099. View